Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

NCT03937154 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03937154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03937154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 26, 2020
Completion date
February 23, 2027
Enrollment
145 (actual)
Sites
139

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced thrombocytopenia